-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
Carfilzomib was developed by Proteolix and then acquired by Onyx Pharmaceuticals.
In 2013, Amgen acquired the drug when it acquired Onyx Pharmaceuticals for $10.
4 billion
According to Amgen’s financial report, Kyprolis’s sales have risen year by year since its listing, and it has become a blockbuster product in 2019, which exceeded $1 billion
.
However, in 2020, the sales growth of the drug has slowed down significantly.
I don't know if it is affected by the new crown epidemic
According to the Insight database, at present, domestic companies have begun to deploy the carfilzomi generic drug market, and most of them have been approved for clinical trials.
Tigermed is progressing rapidly and is in the phase III clinical stage
Speaking of proteasome inhibitors, currently two drugs have been approved in China, namely bortezomib and ixazomib, and both drugs have now entered the national medical insurance
.
The original research bortezomib (Velcade) was developed by Millennium Pharmaceuticals and later acquired by Takeda.
It was approved in the United States in 2003 and domestically in 2005 under the trade name Velcade.
In addition to MM, the approved indications include sets Cell lymphoma
.
Velcade is currently a proteasome inhibitor with high sales, with sales of US$1.
The original research ixazomib (Ninlaro) was developed by Takeda and was approved in the U.
In addition, China has independently developed new proteasome inhibitors, such as Ningbo Shengjian Biopharmaceutical CX13-608 (Phase II clinical) and CTQTQB3602 (Phase I clinical)
